Crossmark

Authors’ Reply to Tsivgoulis et al.: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”

Crossref DOI link: https://doi.org/10.1007/s40263-019-00616-4

Published Online: 2019-02-26

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Papadopoulos, Dimitrios

Mitsikostas, Dimos-Dimitrios D.
License Information

Text and Data Mining valid from 2019-02-26
More Information

Article History

First Online: 26 February 2019

Compliance with Ethical Standards

:

: DP has received consulting, speaking fees and travel grants from Bayer, Genesis Pharma, Merck, Novartis, Roche, Sanofi-Aventis, Specifar and Teva. DDM has received consulting, speaking fees and travel grants from Allergan, Amgen, Cefaly, ElectroCore, Genesis Pharma, Eli Lilly, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Specifar and Teva.

: No funding source had a role in the conception and preparation of this letter.

Document is current

Any future updates will be listed below